Six Biotech Companies in Berlin to Watch in 2026

Why It Matters

These milestones underscore Berlin’s emergence as a world‑class hub for cutting‑edge oncology, regenerative and metabolic therapies, attracting major partnerships and capital that could accelerate drug development pipelines.

Key Takeaways

• 3B partners with Novartis, advancing FAP‑2286 radioligand.
• Ariceum doses first patient; FDA orphan designation granted.
• Captain T Cell secures $23.2M to develop TCR‑T therapies.
• MyoPax receives $2.8M grant; highlights regenerative stem cells.
• OMEICOS shows mitochondrial fitness gains in phase 2a.

Pulse Analysis

Berlin’s biotech ecosystem, anchored by roughly 300 companies and 8,200 employees, benefits from a dense network of universities, research institutes, and the Charité hospital. This infrastructure fuels rapid translation of academic discoveries into commercial programs, positioning the region as Europe’s second‑largest life‑science cluster after London. The city’s supportive funding landscape, including EU grants and venture capital, further amplifies its attractiveness to both domestic innovators and multinational partners.

On the oncology front, Berlin firms are pushing the boundaries of radiopharmaceuticals and cellular immunotherapy. 3B’s partnership with Novartis and its astatine‑211 collaboration illustrate a growing confidence in alpha‑emitter therapies, while Ariceum’s first‑in‑human dosing and orphan‑drug designation signal regulatory momentum for targeted radioligands. Simultaneously, Captain T Cell’s $23.2 million raise reflects investor appetite for next‑generation T‑cell platforms capable of overcoming solid‑tumor resistance, a critical hurdle in cancer treatment.

Beyond cancer, the city’s innovators are tackling unmet needs in muscle regeneration and mitochondrial disease. MyoPax’s scalable satellite‑cell technology promises autologous and allogeneic therapies for muscular dystrophies, bolstered by a $2.8 million EU grant and high‑visibility BIO‑Europe exposure. OMEICOS’s phase 2a success with OMT‑28 demonstrates the therapeutic potential of synthetic omega‑3 analogues to restore mitochondrial function, paving the way for larger trials. Collectively, these advances highlight Berlin’s capacity to nurture diverse biotech modalities, suggesting a sustained pipeline of breakthroughs that could reshape global healthcare markets.